(Press-News.org) WHITEHOUSE STATION, N.J., May 2, 2011 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that new Phase III data showed that patients with open-angle glaucoma or ocular hypertension, who were dosed once-daily with tafluprost, Merck's investigational, preservative-free prostaglandin analogue ophthalmic solution, experienced a reduction in intraocular pressure (IOP) comparable to patients taking twice-daily preservative-free timolol maleate, a beta-adrenergic antagonist. These findings were presented for the first time at the Association for Research in Vision and Ophthalmology (ARVO) 2011 Annual Meeting, held in Fort Lauderdale, FL.
"These results provide important insight into the efficacy and tolerability profile of this investigational medicine," said Tony Ho, section head of neurology and ophthalmology, Merck. "Merck recognizes the importance in developing new ophthalmic therapies. Tafluprost, if approved, will provide an additional treatment option for patients with open-angle glaucoma or ocular hypertension."
The New Drug Application (NDA) for tafluprost is under review by the U.S. Food & Drug Administration (FDA) for the proposed use in the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension. On April 15, 2009, Merck and Santen Pharmaceutical Co., Ltd. entered into a worldwide licensing agreement for tafluprost. Merck has exclusive commercial rights to tafluprost in Western Europe (excluding Germany), North America, South America, Africa, the Middle East, India and Australia. Santen retains commercial rights to tafluprost in Germany, most countries in Eastern Europe, northern Europe and in countries in the Asia Pacific region, including Japan. Merck provides promotion support to Santen in Germany. Santen will have the option to co-promote tafluprost in the U.S., if approved.
Phase III study design
The twelve-week multi-center, double-masked, randomized, active-controlled non-inferiority Phase III study of 643 patients with open-angle glaucoma or ocular hypertension was designed to evaluate the safety and efficacy of preservative-free (PF) tafluprost once-daily (n=320) and PF timolol twice-daily (n=323) over a 12-week treatment period. The study's primary endpoint was mean IOP change from baseline at nine time points: three times during the day (08:00 hours, 10:00 hours and 16:00 hours) at weeks two, six and 12. A secondary endpoint of the study was the proportion of patients with ≥25 percent reduction in diurnal IOP from baseline to week 12.
Efficacy results
At the beginning of the study, baseline IOPs ranged from 23.8 to 26.1 mmHg in patients treated with PF tafluprost and 23.5 to 26.0 mmHg in those treated with PF timolol. At the 12-week end of the study visit, IOPs ranged from 17.4 to 18.6 mmHg in patients treated with PF tafluprost and 17.9 to 18.5 mmHg in those treated with PF timolol. The IOP-lowering effect of treatment in patients receiving PF tafluprost and PF timolol was achieved by week two and sustained through the end of the study (week 12).
The primary endpoint of the study was measured using the Analysis of Covariance (ANCOVA) statistical method, which tests for significant differences between means taking into consideration baseline IOP and ocular diagnosis. For the primary endpoint, at all nine time points, the difference between treatments in lowering IOP was less than the prespecified 1.5 mmHg non-inferiority margin, demonstrating a comparable IOP-lowering effect in patients treated with PF tafluprost and PF timolol. In four of nine time points the difference between treatments in lowering IOP favored PF tafluprost, based on an upper 95 percent confidence interval limit of less than zero.
In addition, for a secondary endpoint the proportion of patients treated with PF tafluprost and PF timolol with ≥25 percent reduction in diurnal IOP from baseline was 56.7 percent vs. 50.5 percent at week two, 58.7 percent vs. 52.6 percent at week six, and 59.7 percent vs. 55.4 percent at week 12, respectively.
Safety results
The adverse event (AE) profiles of PF tafluprost and PF timolol were assessed over the 12-week study period. Drug-related AEs, as determined by the investigators, were experienced
by 12.2 percent of patients treated with PF tafluprost and 11.1 percent of patients treated with PF timolol. Ocular AEs of special interest assessed for PF tafluprost and PF timolol, respectively, were conjunctival hyperemia (4.4 percent vs. 1.2 percent); ocular pain, stinging, and/or irritation (4.4 percent vs. 4.6 percent); and ocular pruritus (2.5 percent vs. 1.5 percent). The incidence of conjunctival hyperemia, a known prostaglandin-associated adverse event, was higher (p=0.016) in the group receiving PF tafluprost compared to the PF timolol group. Serious AEs were reported in 0.6 percent of patients in the PF tafluprost group and 2.2 percent in the PF timolol group, but none of the AEs reported in either treatment group were assessed by the investigators as drug-related. In the PF tafluprost group, 1.3 percent of patients discontinued because of drug-related AEs, compared with 0.9 percent in the PF timolol group.
Poster presentation
Randomized Clinical Trial of the Efficacy and Safety of Preservative-free Tafluprost and Preservative-free Timolol in Patients with Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT) (Poster # A520).
INFORMATION:
About Merck
Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.merck.com.
About Santen
Santen Pharmaceutical is a pharmaceutical company based in Osaka, Japan, which specializes in ophthalmic and anti-rheumatic fields. Santen contributes to maintaining people's
eyesight and health. Santen applies its efforts mainly in ophthalmology, in order to contribute to the quality of life of the patient and their loved ones, and society as a whole. For details please access www.santen.com.
Forward-looking statement
This news release includes "forward-looking statements" within the meaning of the safe
harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such
statements may include, but are not limited to, statements about the benefits of the merger between Merck and Schering-Plough, including future financial and operating results, the combined company's plans, objectives, expectations and intentions and other statements that are not historical facts. Such statements are based upon the current beliefs and expectations of Merck's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements.
The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the possibility that the expected synergies from the merger of Merck and Schering-Plough will not be realized, or will not be realized within the expected time period; the impact of pharmaceutical industry regulation and health care legislation; the risk that the businesses will not be integrated successfully; disruption from the merger making it more difficult to maintain business and operational relationships; Merck's ability to accurately predict future market conditions; dependence on the effectiveness of Merck's patents and other protections for innovative products; the risk of new and changing regulation and health policies in the U.S. and internationally and the exposure to litigation and/or regulatory actions.
Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck's 2010 Annual Report on Form 10-K and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).
Merck's investigational prostaglandin analogue ophthalmic medication tafluprost meets primary endpoint in phase III study
2011-05-02
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
Disastrous IRS Wage Garnishment Averted - Thanks to the Team at Blue Tax!
2011-05-02
Nobody likes paying taxes but the IRS will go to great lengths to ensure they get every penny owed. This includes implementing wage garnishments on taxpayers, which can be humiliating as well as stressful.
This is the situation Alonzo (San Bernardino, CA) found himself in which compelled him to contact Blue Tax for help. Since the experts at Blue Tax deal with wage garnishments regularly, they knew exactly how best to proceed with Alonzo's case.
What Blue Tax quickly discovered was that the client owed a balance of $7,000 to the IRS. A notice of levy had been sent ...
ENERCA clinical recommendations for sickle cell disease management and prevention in children
2011-05-02
ENERCA is a European Network for Rare and Congenital Anaemias funded by the European Commission and coordinated by IDIBAPS - Hospital Clínic of Barcelona. Its main purpose is offering an improved public health service to medical practitioners and patients in every aspect of rare anaemias. Recently this year this network published in the American Journal of Hematology (AJH) a series of recommendations for disease management and prevention of complications of sickle cell disease (SCD) in children. With this of publication ENERCA is willing to give clinical guidance to professional ...
Pain and itch connected down deep
2011-05-02
A new study of itch adds to growing evidence that the chemical signals that make us want to scratch are the same signals that make us wince in pain.
The interactions between itch and pain are only partly understood, said itch and pain researcher Diana Bautista, an assistant professor of molecular and cell biology at the University of California, Berkeley. The skin contains some nerve cells that respond only to itch and others that respond only to pain. Others, however, respond to both, and some substances cause both itching and pain.
If itch and pain are closely linked, ...
Swingers Enjoying Twitter
2011-05-02
Since SwingLifeStyle launched its Twitter account, more swingers are tuning in to the microblogging site for instant updates in the swinger world.
Recently SwingLifeStyle has launched a swingers blog that became an overnight success with thousands of followers in a few days. Swingers are tuning in to Twitter to receive updates from the blog postings as well as other swinger related events. -I have my mobile phone hooked up to twitter and SwingLifeStyle so I don't miss any swinger parties - Mike Hatcher
Most of the followers on Twitter enjoy the instant party updates ...
Endogenous proteins found in a 70-million-year-old giant marine lizard
2011-05-02
With their discovery, the scientists Johan Lindgren, Per Uvdal, Anders Engdahl, and colleagues have demonstrated that remains of type I collagen, a structural protein, are retained in a mosasaur fossil.
The scientists have used synchrotron radiation-based infrared microspectroscopy at MAX-lab in Lund, southern Sweden, to show that amino acid containing matter remains in fibrous tissues obtained from a mosasaur bone.
Previously, other research teams have identified collagen-derived peptides in dinosaur fossils based on, for example, mass spectrometric analyses of whole ...
Caves and their dripstones tell us about the uplift of mountains
2011-05-02
In one of his songs Bob Dylan asks "How many years can a mountain exist before it is washed to the sea?", and thus poses an intriguing geological question for which an accurate answer is not easily provided. Mountain ranges are in a constant interplay between climatically controlled weathering processes on the one hand and the tectonic forces that cause folding and thrusting and thus thickening of the Earth's crust on the other hand. While erosion eventually erases any geological obstacles, tectonic forces are responsible for piling- and lifting-up rocks and thus for forming ...
Statins may stave off septic lung damage says new research study
2011-05-02
Statins may be best known for their ability to reduce cholesterol, but a research report appearing in the May 2011 issue of the Journal of Leukocyte Biology (http://www.jleukbio.org) shows that these same drugs could also play a crucial role in the reduction of lung damage resulting from severe abdominal sepsis and infection.
"We hope that this study will not only provide new knowledge about the complicated pathophysiology behind abdominal sepsis, but also form the basis for more effective and specific treatment options for patients with severe infections," said Henrik ...
Lichen evolved on 2 tracks, like marsupials and mammals
2011-05-02
DURHAM, N.C. – Lichen, those drab, fuzzy growths found on rocks and trees, aren't as cuddly and charismatic as kangaroos or intriguing as opossums, but they could be a fungal equivalent, at least evolutionarily.
A Duke research team has found that lichen that seem identical in all outward appearances and produce the same internal chemicals are in fact two different species, one living in North America and one in Australia. They're an example of "convergent evolution," in which two species evolve separately but end up looking very similar, like the Tasmanian wolf and the ...
Establishing the first line of human embryonic stem cells in Brazil
2011-05-02
Tampa, Fla. (May 2, 2011) – Brazilian researchers, reporting in the current issue of Cell Transplantation (20:3) (now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/ ), discovered difficulties in establishing a genetically diverse line of human embryonic stem cells (hES) to serve the therapeutic stem cell transplantation needs of the diverse ethnic and genetic Brazilian population.
According to the study's corresponding author, Dr. Lygia V. Pereira of the Molecular Genetics Laboratory at the University of Sao Paulo, Brazil, pluripotent human ...
Paging Han Solo: Researchers find more efficient way to steer laser beams
2011-05-02
For many practical applications involving lasers, it's important to be able to control the direction of the laser beams. Just ask Han Solo, or the captain of the Death Star. Researchers from North Carolina State University have come up with a very energy-efficient way of steering laser beams that is precise and relatively inexpensive.
"In many cases, it is much easier to redirect a laser beam at a target than to steer the laser itself. We intended to develop a way to do this efficiently and without moving anything," says Dr. Michael Escuti, an associate professor of electrical ...